Jubilant Pharmova Moat Analysis: Score & Risks
Jubilant Pharmova Ltd.
A first-pass moat teardown of Jubilant Pharmova Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.
First-pass narrow read — primary edge in Network Effects. Provisional, single-pass evidence.
Jubilant Pharmova Ltd. scores 5.28 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.
Seven dimensions of moat
Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.
“current geographical reach enables it to serve over four million patients yearly”
“we have established contracts with Gilead, Eli Lilly and Novavax for the manufacturing of vaccines and therapeutic drugs to fight the pandemic.”
“The business derives benefit of backward integration with a part of our commercial Solid Dosage Formulations backward integrated to in-house APIs. This helps us reduce costs and maintain optimal efficiency.”
“Risk mitigation is planned by focusing business efforts towards more profitable market applications which are also less price sensitive.”
“We continue to develop NCE-1 molecules meant for FTF opportunities and evaluate options for 505(b) (2) and Day 1/181 launches, focusing on sustainable and competitive offerings to customer.”
“in October, we received continuation of the similar status, which was OAI with import alert”
D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.
The barrier gate — first-pass
Effective barrier 6 — at or above 6, consistent with a narrow read. First-pass estimate.
Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.
Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.
Where this note fits. This company is one of 509 Indian companies we have scored for moat durability — 370 narrow, 126 narrow-trending-wide, none wide. Every score, dimension by dimension, is free in the Moat Screener.
Member discussion